熱門資訊> 正文

Longleaf Partners Fund退出BOP

2026-07-13 22:35

Bio-Rad實驗室(BIO) 0

Longleaf Partners Fund underperformed with a return of 3.87% in Q2, as compared to the S&P 500's 15.20% gain and the Russell 1000 Value Index's 13.87% advance.
The fund initiated one new position in a healthcare company during Q2 2026.
In Q2 2026, the fund exited Bio-Rad (NYSE: BIO).
Source.

More on Longleaf Partners Fund, Bio-Rad Laboratories, Inc.

Longleaf Partners Fund Q2 2026 Commentary
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential
Bio-Rad Laboratories, Inc. (BIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Longleaf Partners Fund exits BIO
These 10 mid-cap U.S. healthcare companies rank among the market's most attractively valued stocks

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。